240 related articles for article (PubMed ID: 37532520)
1. Genetic inhibitors of APOBEC3B-induced mutagenesis.
Mertz TM; Rice-Reynolds E; Nguyen L; Wood A; Cordero C; Bray N; Harcy V; Vyas RK; Mitchell D; Lobachev K; Roberts SA
Genome Res; 2023 Sep; 33(9):1568-1581. PubMed ID: 37532520
[TBL] [Abstract][Full Text] [Related]
2. Genetic modifiers of APOBEC-induced mutagenesis.
Mertz TM; Rice-Reynolds E; Nguyen L; Wood A; Bray N; Mitchell D; Lobachev K; Roberts SA
bioRxiv; 2023 Apr; ():. PubMed ID: 37066362
[TBL] [Abstract][Full Text] [Related]
3. APOBEC3A is a prominent cytidine deaminase in breast cancer.
Cortez LM; Brown AL; Dennis MA; Collins CD; Brown AJ; Mitchell D; Mertz TM; Roberts SA
PLoS Genet; 2019 Dec; 15(12):e1008545. PubMed ID: 31841499
[TBL] [Abstract][Full Text] [Related]
4. APOBEC3A and APOBEC3B Preferentially Deaminate the Lagging Strand Template during DNA Replication.
Hoopes JI; Cortez LM; Mertz TM; Malc EP; Mieczkowski PA; Roberts SA
Cell Rep; 2016 Feb; 14(6):1273-1282. PubMed ID: 26832400
[TBL] [Abstract][Full Text] [Related]
5. APOBEC3B cytidine deaminase targets the non-transcribed strand of tRNA genes in yeast.
Saini N; Roberts SA; Sterling JF; Malc EP; Mieczkowski PA; Gordenin DA
DNA Repair (Amst); 2017 May; 53():4-14. PubMed ID: 28351647
[TBL] [Abstract][Full Text] [Related]
6. Distinguishing preferences of human APOBEC3A and APOBEC3B for cytosines in hairpin loops, and reflection of these preferences in APOBEC-signature cancer genome mutations.
Butt Y; Sakhtemani R; Mohamad-Ramshan R; Lawrence MS; Bhagwat AS
Nat Commun; 2024 Mar; 15(1):2369. PubMed ID: 38499553
[TBL] [Abstract][Full Text] [Related]
7. Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment.
Vural S; Simon R; Krushkal J
Hum Genomics; 2018 Apr; 12(1):20. PubMed ID: 29642934
[TBL] [Abstract][Full Text] [Related]
8. Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells.
Yamazaki H; Shirakawa K; Matsumoto T; Hirabayashi S; Murakawa Y; Kobayashi M; Sarca AD; Kazuma Y; Matsui H; Maruyama W; Fukuda H; Shirakawa R; Shindo K; Ri M; Iida S; Takaori-Kondo A
Sci Rep; 2019 May; 9(1):7122. PubMed ID: 31073151
[TBL] [Abstract][Full Text] [Related]
9. APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replication.
Seplyarskiy VB; Soldatov RA; Popadin KY; Antonarakis SE; Bazykin GA; Nikolaev SI
Genome Res; 2016 Feb; 26(2):174-82. PubMed ID: 26755635
[TBL] [Abstract][Full Text] [Related]
10. Protein kinase A inhibits tumor mutator APOBEC3B through phosphorylation.
Matsumoto T; Shirakawa K; Yokoyama M; Fukuda H; Sarca AD; Koyabu S; Yamazaki H; Kazuma Y; Matsui H; Maruyama W; Nagata K; Tanabe F; Kobayashi M; Shindo K; Morishita R; Sato H; Takaori-Kondo A
Sci Rep; 2019 Jun; 9(1):8307. PubMed ID: 31165764
[TBL] [Abstract][Full Text] [Related]
11. Heat shock proteins stimulate APOBEC-3-mediated cytidine deamination in the hepatitis B virus.
Chen Z; Eggerman TL; Bocharov AV; Baranova IN; Vishnyakova TG; Kurlander R; Patterson AP
J Biol Chem; 2017 Aug; 292(32):13459-13479. PubMed ID: 28637869
[TBL] [Abstract][Full Text] [Related]
12. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers.
Chan K; Roberts SA; Klimczak LJ; Sterling JF; Saini N; Malc EP; Kim J; Kwiatkowski DJ; Fargo DC; Mieczkowski PA; Getz G; Gordenin DA
Nat Genet; 2015 Sep; 47(9):1067-72. PubMed ID: 26258849
[TBL] [Abstract][Full Text] [Related]
13. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors.
Middlebrooks CD; Banday AR; Matsuda K; Udquim KI; Onabajo OO; Paquin A; Figueroa JD; Zhu B; Koutros S; Kubo M; Shuin T; Freedman ND; Kogevinas M; Malats N; Chanock SJ; Garcia-Closas M; Silverman DT; Rothman N; Prokunina-Olsson L
Nat Genet; 2016 Nov; 48(11):1330-1338. PubMed ID: 27643540
[TBL] [Abstract][Full Text] [Related]
14. Avoidance of APOBEC3B-induced mutation by error-free lesion bypass.
Hoopes JI; Hughes AL; Hobson LA; Cortez LM; Brown AJ; Roberts SA
Nucleic Acids Res; 2017 May; 45(9):5243-5254. PubMed ID: 28334887
[TBL] [Abstract][Full Text] [Related]
15. APOBEC3B high expression status is associated with aggressive phenotype in Japanese breast cancers.
Tsuboi M; Yamane A; Horiguchi J; Yokobori T; Kawabata-Iwakawa R; Yoshiyama S; Rokudai S; Odawara H; Tokiniwa H; Oyama T; Takeyoshi I; Nishiyama M
Breast Cancer; 2016 Sep; 23(5):780-8. PubMed ID: 26476745
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of APOBEC3A and 3B expression in patients with breast cancer.
Kim YS; Sun S; Yoon JS; Ko YH; Won HS; Kim JS
PLoS One; 2020; 15(3):e0230261. PubMed ID: 32176735
[TBL] [Abstract][Full Text] [Related]
17. FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis.
Waters CE; Saldivar JC; Amin ZA; Schrock MS; Huebner K
Oncotarget; 2015 Feb; 6(5):3409-19. PubMed ID: 25401976
[TBL] [Abstract][Full Text] [Related]
18. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis.
Taylor BJ; Nik-Zainal S; Wu YL; Stebbings LA; Raine K; Campbell PJ; Rada C; Stratton MR; Neuberger MS
Elife; 2013 Apr; 2():e00534. PubMed ID: 23599896
[TBL] [Abstract][Full Text] [Related]
19. Targeting natural splicing plasticity of APOBEC3B restricts its expression and mutagenic activity.
Rouf Banday A; Onabajo OO; Lin SH; Obajemu A; Vargas JM; Delviks-Frankenberry KA; Lamy P; Bayanjargal A; Zettelmeyer C; Florez-Vargas O; Pathak VK; Dyrskjøt L; Prokunina-Olsson L
Commun Biol; 2021 Mar; 4(1):386. PubMed ID: 33753867
[TBL] [Abstract][Full Text] [Related]
20. APOBEC3B expression in breast cancer cell lines and tumors depends on the estrogen receptor status.
Udquim KI; Zettelmeyer C; Banday AR; Lin SH; Prokunina-Olsson L
Carcinogenesis; 2020 Aug; 41(8):1030-1037. PubMed ID: 31930332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]